|
Volumn 21, Issue 4, 2008, Pages 392-394
|
Do we have the same clinical results with Neoral® and Equoral® treatment in kidney transplant recipients? A pilot study
a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
CORTICOSTEROID;
CYCLOSPORIN A;
DACLIZUMAB;
EQUORAL;
METHYLPREDNISOLONE;
MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;
PREDNISOLONE;
THYMOCYTE ANTIBODY;
UNCLASSIFIED DRUG;
CYCLOSPORIN;
IMMUNOSUPPRESSIVE AGENT;
ABSENCE OF SIDE EFFECTS;
BIOEQUIVALENCE;
DRUG ABSORPTION;
DRUG BIOAVAILABILITY;
DRUG COST;
DRUG FORMULATION;
HUMAN;
IMMUNOSUPPRESSIVE TREATMENT;
KIDNEY GRAFT REJECTION;
KIDNEY TRANSPLANTATION;
LETTER;
PILOT STUDY;
PRIORITY JOURNAL;
ADULT;
COMPARATIVE STUDY;
FEMALE;
MALE;
PHARMACOKINETICS;
RETROSPECTIVE STUDY;
TREATMENT OUTCOME;
ADULT;
CYCLOSPORINE;
FEMALE;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
KIDNEY TRANSPLANTATION;
MALE;
PILOT PROJECTS;
RETROSPECTIVE STUDIES;
THERAPEUTIC EQUIVALENCY;
TREATMENT OUTCOME;
|
EID: 40449084503
PISSN: 09340874
EISSN: 14322277
Source Type: Journal
DOI: 10.1111/j.1432-2277.2007.00612.x Document Type: Letter |
Times cited : (9)
|
References (9)
|